Iovance Biotherapeutics, Inc. develops and commercializes novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. Company news commonly addresses Amtagvi, described by Iovance as the first FDA-approved T cell therapy for a solid tumor indication, Proleukin, lifileucel, and pipeline work across solid tumor cancers.
Recurring updates include clinical data, regulatory disclosures, operating and financial results, corporate presentations, material agreements, and governance matters. Iovance also reports Nasdaq inducement equity grants under its Amended and Restated 2021 Inducement Plan as part of its public-company compensation disclosures.
Iovance Biotherapeutics has announced upcoming presentations at various virtual healthcare conferences. Key events include the Cowen 41st Annual Health Care Conference on March 3 at 1:20 p.m. ET, H.C. Wainwright Global Life Sciences Conference on March 9 at 7:00 a.m. ET, Barclays Global Healthcare Conference on March 11 at 1:50 p.m. ET, and Oppenheimer 31st Annual Healthcare Conference on March 17 at 1:10 p.m. ET. The webcasts of these presentations will be available on the Iovance website.
Iovance Biotherapeutics (NASDAQ: IOVA) reported its Q4 and full-year 2020 financial results, showing a cash position of $635 million, expected to last into 2023. The company emphasized progress in its TIL cell therapies across various cancers, including melanoma and cervical cancer, and plans for a potential BLA submission in 2021. R&D expenses rose to $201.7 million for the year, while general and administrative expenses increased to $60.2 million. The net loss for Q4 was $68.4 million, with a full-year net loss of $259.6 million.
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) will release its fourth quarter and full year 2020 financial results on February 25, 2021. A conference call will follow at 4:30 p.m. EST to discuss these results. The company focuses on T cell-based cancer immunotherapies, having completed pivotal programs for metastatic melanoma and cervical cancer. Iovance is also investigating tumor infiltrating lymphocyte (TIL) therapy for non-small cell lung cancer and earlier-stage cancers. For further information, visit www.iovance.com.
Iovance Biotherapeutics (NASDAQ: IOVA) announced participation in three upcoming virtual healthcare conferences to discuss advancements in T cell-based cancer therapies. The sessions include:
- B. Riley Oncology Investor Conference: January 20, 2021, at 1:00 p.m. ET.
- Guggenheim Healthcare Talks Oncology Days: February 11, 2021, at 12:00 p.m. ET.
- 7th Annual Immuno-Oncology 360° Conference: Panel on February 23, 2021, at 11:10 a.m. ET, followed by a presentation on TIL therapy at 1:45 p.m. ET.
Webcasts will be available on Iovance's Investor website.
Iovance Biotherapeutics, a late-stage biotechnology company, has announced that its CEO, Maria Fardis, will present at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021, at 10:50 a.m. ET. Iovance is focused on T cell-based cancer immunotherapies, particularly tumor-infiltrating lymphocyte (TIL) therapy, which utilizes a patient's own immune cells to combat cancer. The company has completed dosing in pivotal studies for metastatic melanoma and cervical cancer. Further, Iovance's therapies are exploring treatment for various advanced cancers.
Iovance Biotherapeutics (NASDAQ: IOVA) has appointed Jean-Marc Bellemin as Chief Financial Officer, a move aimed at enhancing the company's strategic financial oversight. Bellemin brings 27 years of experience, including significant roles in public biopharma companies. His previous positions include CFO at Gritstone Oncology and Actelion Pharmaceuticals, where he contributed to substantial revenue growth and multiple product launches. The appointment is timely as Iovance transitions toward commercializing TIL cell therapy for cancer treatment, with ongoing clinical studies in advanced stages.
Iovance Biotherapeutics, a late-stage biotechnology firm focused on T cell-based cancer immunotherapies, announced presentations at key conferences from December 1-3, 2020. Events include the Piper Sandler 32nd Annual Virtual Healthcare Conference, and the Cellular Immunotherapies for Solid Tumors Summit, where they will discuss the clinical success of their TIL technology. The company is advancing TIL therapy for various cancers, including metastatic melanoma and cervical cancer. Webcasts of the presentations will be available on their website.
Iovance Biotherapeutics (NASDAQ: IOVA) presented interim data for its tumor infiltrating lymphocyte (TIL) therapy, LN-145, combined with pembrolizumab for advanced head and neck squamous cell carcinoma (HNSCC). The study showed a 44.4% overall response rate (ORR) and a disease control rate of 88.9%, with a median duration of response not yet reached at 8.6 months. The trial participants were PD-1 blockade naive, and 89% had progressed on prior chemotherapy. Iovance continues to explore additional solid tumor indications for this combination therapy.
Iovance Biotherapeutics (NASDAQ: IOVA) reported its third quarter 2020 results alongside a corporate update, highlighting an agreement with the FDA to move the BLA submission for lifileucel to 2021. The company initiated a registration-directed study for lung cancer and reported strong financials with $719.7 million in cash. However, net losses increased to $58.6 million in Q3 2020. R&D expenses grew due to clinical trials and internal team expansion. Iovance aims to lead in TIL therapy development and is set to present data at the SITC Annual Meeting.
Iovance Biotherapeutics (NASDAQ: IOVA) will release its Q3 2020 financial results on November 5, 2020, followed by a conference call at 4:30 p.m. EST for a corporate update. The company focuses on T cell-based cancer immunotherapies, and its pivotal studies include treatments for metastatic melanoma and advanced cervical cancer. Iovance aims to enhance patient care by making immunotherapies accessible for various cancers. Key challenges may impact clinical trial timelines and regulatory approvals, particularly due to COVID-19 and potential FDA feedback.